Skip to main content
. 2013 Jan 7;3:309. doi: 10.3389/fgene.2012.00309

Figure 1.

Figure 1

Barplot reporting the percentage of patients developing severe (Grade 3–4) GI toxicity during consolidation therapy in patients with ALL treated according to the St Jude Total 13B protocol as a function of TPMT rs1142345 / SLCO1B1 rs11045879 / PACSIN2 rs2413739 multilocus genotype (Stocco et al., 2012).